New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 5, 2013
07:17 EDTSNGXSoligenix begins Phase 2 trial of SGX942 for oral mucositis in cancer patients
Soligenix has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942 as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer. This Phase 2 study is a multicenter trial focused on patients with tumors of the mouth and oropharynx who often experience debilitating oral mucositis as a consequence of tumor treatment with intensity modulated radiation and chemotherapy.
News For SNGX From The Last 14 Days
Check below for free stories on SNGX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SNGX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use